Navigation Links
arGEN-X Presents Significant Progress at BioPharm America 2011
Date:9/7/2011

nsforming the therapeutic antibody space. The speed and productivity of our first three internal programs have enabled us to begin discovery work on two new therapeutic targets. These developments have been instrumental in attracting companies seeking a reliable, robust platform for generation of therapeutic grade antibody candidates. Given this progress, I am excited about arGEN-X' prospects for the coming year."

Note for the editor

About arGEN-X - http://www.arGEN-X.com

arGEN-X is a preclinical stage biopharmaceutical company with a broadly applicable, proprietary SIMPLE Antibody™ platform. The platform allows arGEN-X to create an unparalleled diversity of in vivo generated antibody leads against a broad range of human disease targets. This superior choice of ultra-high affinity and highly potent leads, having best-in-class human homology, allows for more stringent lead selection criteria, thereby increasing the probability of success later in the drug development path. The Company has validated its platform on four human disease targets to date and has broad patent claims in place covering its technology.

arGEN-X' SIMPLE Antibody™ Platform is based on the active immunisation of Camelids with target antigens to deliver antibody variable regions that are perfectly matched to those of human antibodies. The combination of those variable domains with the constant domains of human antibodies, generates full size, human therapeutic antibodies.

The SIMPLE Antibody™ Platform enjoys an independent, unencumbered patent position and is free of target gatekeeping restrictions.

arGEN-X™ and SIMPLE Antibody™ are deposited trademarks of arGEN-X BV.

SIMPLE stands for Superior Immunodiversity with Minimal Protein Lead Engineering.

For further information, please contact:


  
'/>"/>

SOURCE arGEN-X
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. arGEN-X Announces Non-Exclusive License With BioWa for POTELLIGENT® Technology
2. arGEN-X Granted Broad Patent Covering its Unique SIMPLE Antibody(TM) Platform
3. arGEN-X SIMPLE Antibody(TM) Platform set to Transform Therapeutic Antibody Discovery & Development
4. arGEN-X Concludes EUR 12.5 Million Series A Financing Round
5. Elan Pharmaceuticals Presents 7th Annual Danville Concours dElegance Weekend
6. Codexis Presents Carbon Capture Update at DoE/NETL Conference
7. Cardium Presents Second Quarter 2011 Financial Results and Reports on Near-Term Milestones
8. Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimers Disease Research
9. Amerigroup Foundation Presents Grant to Rx Partnership
10. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
11. Prime Therapeutics Vice President of Specialty Pharmacy Solutions Presents at 6th Annual Executive Forum on Pharmacy Benefit Management Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... March 30, 2015   GlassesUSA , the online retailer ... $12.5 million in new financing led by Viola Private ... will further GlassesUSA,s aggressive business growth and accelerate their expansion ... online eyewear, both B2C and B2B. GlassesUSA was ... Eldad Rothman , and CTO Roy Yamner . ...
(Date:3/30/2015)... HA,AYIN, Israel , March 30, 2015 ... of Dr. Yuval Avni as the company,s ... partner at Giza VC, a leading early stage Israeli ... with clinical experience in general and vascular surgery.   ... company also announced today that Sherpa Innoventures is Beta-O2,s ...
(Date:3/30/2015)... Pharmaceuticals Corporation (NASDAQ: RXII ), a biotechnology ... primarily in the areas of dermatology and ophthalmology ... financial results for the fourth quarter and year ... update. Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... a steady growth and evolution for RXi Pharmaceuticals," ...
Breaking Medicine Technology:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 2GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 3Beta-O2 Names Dr. Yuval Avni CEO 2Beta-O2 Names Dr. Yuval Avni CEO 3RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 2RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 3RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 4RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 5RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 6RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 7RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 8RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 9RXi Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Recent Corporate Highlights 10
... Thoratec Corporation (NASDAQ: THOR ), a ... to save, support and restore failing hearts, today ... relating to WiTricity,s proprietary wireless resonant energy transfer ... circulatory support. Through a collaborative effort ...
... OMER ), a biopharmaceutical company committed to ... and disorders of the central nervous system, today announced ... Financial ResultsTotal operating expenses for the ... compared to $6.8 million for the same periods in ...
Cached Medicine Technology:Thoratec Announces Development Agreement With WiTricity for Proprietary Energy Transfer Technology 2Thoratec Announces Development Agreement With WiTricity for Proprietary Energy Transfer Technology 3Thoratec Announces Development Agreement With WiTricity for Proprietary Energy Transfer Technology 4Omeros Corporation Reports First Quarter 2011 Financial Results 2Omeros Corporation Reports First Quarter 2011 Financial Results 3Omeros Corporation Reports First Quarter 2011 Financial Results 4
(Date:3/30/2015)... This report studies the global pharmacovigilance and drug ... 2014 to 2019. This market is expected to ... to 2019. , Further Inquiry @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=16831714 ... and drug safety software market has been classified ... namely, adverse event reporting software, drug safety audits ...
(Date:3/30/2015)... New York, New York (PRWEB) March 30, 2015 ... of its Top 10 Exotic Water Awards, with the top ... other winners are listed on the company’s website, along with ... Water’s website, exotic water, glacial water, spring water, mineral water ... Fiji water is one of the top exotic water ...
(Date:3/30/2015)... FMC Corporation’s Health and Nutrition division ... Epax® Ultra and Core concentrates manufactured in the ... ensures the manufacturing process and all physical raw ... for Halal. , The new Halal certification ... advance its customer service to a global market ...
(Date:3/30/2015)... Slidezilla, an app from the makers of ... innovates the fun and simplicity of photo slideshows. The ... slideshows and then instantly share them across their Facebook, ... to create a slideshow app where users can share ... options to personalize them. You can choose your own ...
(Date:3/30/2015)... V/NO (Virtually No Alcohol) Wines have a sleek ... and for reuse. Consumers simply twist the cup, turn it ... professionals, and basically anyone can now enjoy a non-alcoholic ... socially or pair with meals at work, home, or wherever ... and that means Napa Wine grapes undergo the traditional ...
Breaking Medicine News(10 mins):Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4Health News:Best Exotic Water Brands Acclaimed by 10 Best Water 2Health News:FMC Health and Nutrition Announces Halal Certification for Epax® Brand Omega-3 Ingredients 2Health News:Napa Valley Alcohol-Removed Red, White & Rosé Wines Have Launched. 2
... CAWhen cells find themselves in a tight spot, the ... cells time to repair the damage, or if all ... to other stress-induced genes, which dispense with the regular ... factor that also helps with the editing of transcripts, ...
... Loyola University Health System study includes some unexpected ... Contrary to expectations, patients who died from their ... than patients who survived., "Perhaps a better understanding ... for therapies that further improve outcomes in burn ...
... CAWhen cells find themselves in a tight spot, the ... cells time to repair the damage, or if all ... to other stress-induced genes, which dispense with the regular ... factor that also helps with the editing of transcripts, ...
... children and adolescents. In the current issue of ... 173-79), Susanne Walitza and her colleagues point out that ... course of the disease. Compulsive washing, the most ... in up to 87% of all patients; other common ...
... The United States should pay close attention to how the ... worth using factors that go beyond clinical and cost effectiveness, ... Bioethics. In a commentary to appear in the April ... , the bioethicists detail and discuss a new, "value-based pricing" ...
... establishes a unique system to perform in vivo ... networks that regulate hepatocyte proliferation during chronic liver ... that stable knockdown of the candidate gene by ... of mouse hepatocytes and also increase the regenerative ...
Cached Medicine News:Health News:'SKIP'-ing splicing forces tumor cells to undergo programmed cell death 2Health News:'SKIP'-ing splicing forces tumor cells to undergo programmed cell death 3Health News:Surprising finding from smoke inhalation study 2Health News:‘SKIP’-ing splicing forces tumor cells to undergo programmed cell death 2Health News:‘SKIP’-ing splicing forces tumor cells to undergo programmed cell death 3Health News:Placing value, price on new drugs: The challenge facing new UK policy, say Hopkins bioethicists 2Health News:Placing value, price on new drugs: The challenge facing new UK policy, say Hopkins bioethicists 3
... developing diverse medical products for ... medical-surgical products have earned an ... and customer satisfaction. Graham-Fields internationally ... line of diagnostic instruments, Grafco® ...
Pediatric Compressor Nubulizer...
The 45 PSI SuperSportNeb provides superior performance that translates to shorter treatment times. Like the SportNeb, it is constructed with die-cast aluminum compressor components for consistent rel...
The TransNeb is a complete medication delivery system in a bag. The TransNeb is a compact, piston compressor providing high-performance while weighing only 11 oz. Versatility. Dependability. Simplici...
Medicine Products: